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Introduction 
The aim of this study was to examine the contribution of anti-tumor immunity for the efficacy 
of oncolytic reovirus therapy against multiple myeloma (MM). Oncolytic viruses (OV) have 
two main mechanisms of action; direct lytic killing and potentiation of anti-tumor immunity. 
The direct oncolytic potential of reovirus in MM has previously been demonstrated both in 
vitro and in vivo, but the importance of an enhanced immunological anti-tumor response 
remains under-investigated. Reovirus-induced anti-tumor immunity has been demonstrated 
in other types of cancer such as melanoma and chronic leukemia, and is of major importance 
for the efficacy of OV treatment. Thus, it was hypothesized that reovirus-induced anti-
myeloma immunity would contribute significantly to the efficacy of reovirus treatment for 
MM. 
 
Experimental procedures 
C57BL/KaLwRij mice were used in the 5TGM1 model system to establish MM in vivo. This 
model closely resembles human MM with induction of osteolytic bone disease and secretion 
of paraprotein. C57BL/KaLwRij mice have a fully functional immune system, comparable to 
C57BL/6 mice, and to our knowledge, this is the first immunocompetent model of MM for the 
study of reovirus efficacy. After establishment of MM in the bone by intravenous injection of 
bone-homing 5TGM1 cells, mice were treated with repeated injections of reovirus or PBS.  
Upon sacrifice, direct cytotoxicity and immune activation was examined using flow cytometry. 
All animal experiments were performed under an appropriate project license following 
approval by a local ethical review committee. In vivo findings were translated into human in 
vitro studies, using MM cell lines, healthy donor (HD) blood and MM patient samples. 
Reovirus-induced Natural Killer (NK) cell activation and degranulation was examined using 
flow cytometry and priming of myeloma-specific T cells was performed using long-term 
priming cultures. 
 
Results 
Tumor burden was reduced by reovirus treatment both in the bone marrow (BM) and spleen 
of tumor-bearing mice. The immune cell populations, including NK cells, CD4+ T cells and CD8+ 
T cells were restored to levels of tumor naïve mice in the BM. NK cells were activated in the 
BM following reovirus treatment, which indicates the onset of an innate immune response. 
In the spleen, an increase in CD4+ T cells, in combination with CD8+ activation was indicative 
of an early adaptive immune response. These results translate into human in vitro findings, 
using both HD and MM patient samples, with activation of NK cells in response to reovirus 
treatment and subsequent enhancement of NK cell degranulation and killing of MM target 
cells. Encouragingly, reovirus-activated NK cells were able to kill OPM2 cells, which are 
resistant to direct lytic killing. Preliminary human in vitro studies suggest that reovirus 
treatment can prime anti-myeloma CD8+ T cells for the induction of a long-term protective 
response. 
 
Conclusions 
Introducing a viral agent into the body requires a delicate immunological balance to avoid 
neutralizing the virus by an antiviral response and simultaneously allowing the enhancement 
of anti-tumor immunity. The importance of enhanced anti-tumor immunity for OV therapy 
efficacy is becoming more widely recognized and antiviral immunity can in some 
circumstances contribute to tumor eradication. The findings in this study indicate that the 
anti-tumor immune response is also important in the MM setting, with activation of both 
innate and adaptive immune responses resulting in enhanced killing of MM cells, in particular 
those resistant to direct lytic killing. This suggests that both arms of OV therapy could play a 
role for MM eradication, including any minimal residual disease. Future work will explore 
whether the anti-myeloma response can be further enhanced by combinatorial treatments, 
including current standard of care treatments. 
 
